Current Atherosclerosis Reports

, Volume 8, Issue 3, pp 245–251 | Cite as

Cyclooxygenase-2 inhibition: Vascular inflammation and cardiovascular risk

Article

Abstract

The inducible isoform of cyclooxygenase-2 (COX-2) plays a role in pathophysiologic processes like inflammation and pain but is also constitutively expressed in tissues such as the kidney or vascular endothelium, where it exerts important physiologic functions. Although much evidence exists that implicates COX-2 in atherosclerosis, its role in this setting remains substantially uncertain. This observation is also confirmed by the results of clinical trials of selective COX-2 inhibitors. Treatment with these drugs, developed with the assumption that they would be as effective as nonselective COX inhibitors but without their gastrointestinal side effects, has been reported to be associated with an increased cardiovascular risk. In this article, we review the pattern of expression of COX-2 in the cellular players of atherothrombosis, its role as a determinant of plaque vulnerability, and the vascular effects on prostanoid inhibition by COX-2 inhibitors.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.PubMedCrossRefGoogle Scholar
  2. 2.
    Cipollone F, Prontera C, Pini B, et al.: Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001, 104:921–927.PubMedGoogle Scholar
  3. 3.
    Cipollone F, Fazia M, Iezzi A, et al.: Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol 2004, 24:1259–1265.PubMedCrossRefGoogle Scholar
  4. 4.
    Baigent C, Patrono C: Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum 2003, 48:12–20.PubMedCrossRefGoogle Scholar
  5. 5.
    Dubois RN, Abramson SB, Crofford L, et al.: Cyclooxygenase in biology and disease. FASEB J 1998, 12:1063–1073.PubMedGoogle Scholar
  6. 6.
    Smith WL, Langenbach R: Why there are two cyclooxygenase isozymes. J Clin Invest 2001, 107:1491–1495.PubMedCrossRefGoogle Scholar
  7. 7.
    Patrono C: Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage?. Thromb Res 1998, 92:S7-S12.PubMedCrossRefGoogle Scholar
  8. 8.
    Xie W, Chipman JG, Roberson DL, et al.: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991, 88:2682–2686.Google Scholar
  9. 9.
    Cipollone F, Fazia M, Mezzetti A: Novel determinants of plaque instability. J Thromb Haemost 2005, 3:1962–1975.PubMedCrossRefGoogle Scholar
  10. 10.
    Hong BK, Kwon HM, Lee BK, et al.: Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J 2000, 41:82–88.PubMedGoogle Scholar
  11. 11.
    Burleigh ME, Babaev VR, Oates JA, et al.: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002, 105:1816–1823.PubMedCrossRefGoogle Scholar
  12. 12.
    Maier JA, Barenghi L, Bradamante S, Pagani F: Modulators of oxidized LDL-induced hyperadhesiveness in human endothelial cells. Biochem Biophys Res Commun 1994, 204:673–677.PubMedCrossRefGoogle Scholar
  13. 13.
    Cipollone F, Rocca B, Patrono C: Cyclooxygenase-2 expression and inhibition in atherotrombosis. Arterioscler Thromb Vasc Biol 2004, 24:246–255.PubMedCrossRefGoogle Scholar
  14. 14.
    Kreuzer J, Denger S, Jahn L, et al.: LDL stimulates chemotaxis of human monocytes through a cyclooxygenase-dependent pathway. Arterioscler Thromb Vasc Biol 1996, 16:1481–1487.PubMedGoogle Scholar
  15. 15.
    Praticò D, Tillmann C, Zhang ZB, et al.: Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A 2001, 98:3358–3363.PubMedCrossRefGoogle Scholar
  16. 16.
    Olesen M, Kwong E, Meztli A, et al.: No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J 2002, 36:362–367.PubMedCrossRefGoogle Scholar
  17. 17.
    Rott D, Zhu J, Burnett MS, et al.: Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol 2003, 41:1812–1819.PubMedCrossRefGoogle Scholar
  18. 18.
    Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 1994, 330:1287–1294.PubMedCrossRefGoogle Scholar
  19. 19.
    Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K: Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999, 353:900.PubMedCrossRefGoogle Scholar
  20. 20.
    Rocca B, Secchiero P, Ciabattoni G, et al.: Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002, 99:7634–7639.PubMedCrossRefGoogle Scholar
  21. 21.
    Cipollone F, Iezzi A, Iezzi M, et al.: Aspirin-insensitive myocardial infarction is associated with overexpression of cyclooxygenase-2 in coronary thrombi [abstract]. Circulation 2004, 110:354.Google Scholar
  22. 22.
    Rolland PH, Jouve R, Pellegrin E, et al.: Alteration in prostacyclin and prostaglandin E2 production. Correlation with changes in human aortic atherosclerotic disease. Arteriosclerosis 1984, 4:70–78.PubMedGoogle Scholar
  23. 23.
    Wong E, Huang JQ, Tagari P, Riendeau D: Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis 2001, 157:393–402.PubMedCrossRefGoogle Scholar
  24. 24.
    Cipollone F, Fazia M, Iezzi A, et al.: Suppression of the functionally coupled cyclooxygenase-2/PGE synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003, 107:1479–1485.PubMedCrossRefGoogle Scholar
  25. 25.
    Cipollone F, Fazia M, Iezzi A, et al.: Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004, 109:1482–1488.PubMedCrossRefGoogle Scholar
  26. 26.
    Murakami M, Naraba H, Tanioka T, et al.: Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000, 275:32783–32792.PubMedCrossRefGoogle Scholar
  27. 27.
    Cipollone F, Iezzi A, Fazia M, et al.: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003, 108:1070–1077.PubMedCrossRefGoogle Scholar
  28. 28.
    Cipollone F, Fazia M, Iezzi A, et al.: Reduced FACL-4 expression in vulnerable atherosclerosis plaques as a basis of PGE2-dependent plaque instability. Circulation 2002, 106:II44.Google Scholar
  29. 29.
    Cipollone F, Fazia ML, Iezzi A, et al.: Association between prostaglandin E receptor subtype EP4 over-expression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol 2005, 25:1925–1931.PubMedCrossRefGoogle Scholar
  30. 30.
    Papafili A, Hill MR, Brull DJ, et al.: A common promoter variant in cyclooxygenase-2 represses gene expression: evidence for a role in the acute phase inflammatory response. Arterioscler Thromb Vasc Biol 2002, 22:1631–1636.PubMedCrossRefGoogle Scholar
  31. 31.
    Cipollone F, Patrono C: Cyclooxygenase-2 polymorphism. Putting a brake on the inflammatory response to vascular injury? Arterioscler Thromb Vasc Biol 2002, 22:1516–1518.PubMedCrossRefGoogle Scholar
  32. 32.
    Cipollone F, Toniato E, Martinotti S, et al.: Identification of New Elements of Plaque Stability (INES) study group. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004, 291:2221–2228.PubMedCrossRefGoogle Scholar
  33. 33.
    FitzGerald GA, Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345:433–442.PubMedCrossRefGoogle Scholar
  34. 34.
    Wolfe F, Anderson J, Burke TA, et al.: Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002, 29:467–473.PubMedGoogle Scholar
  35. 35.
    Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR study group. N Engl J Med 2000, 343:1520–1528.PubMedCrossRefGoogle Scholar
  36. 36.
    Capone ML, Tacconelli S, Sciulli MG, et al.: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004, 109:1468–1471.PubMedCrossRefGoogle Scholar
  37. 37.
    Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092–1102.PubMedCrossRefGoogle Scholar
  38. 38.
    Solomon SD, McMurray JV, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071–1080.PubMedCrossRefGoogle Scholar
  39. 39.
    Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000, 284:1247–1255.PubMedCrossRefGoogle Scholar
  40. 40.
    Ott E, Nussmeier NA, Duke PC, et al.: Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003, 125:1481–1492.PubMedCrossRefGoogle Scholar
  41. 41.
    Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081–1091.PubMedCrossRefGoogle Scholar
  42. 42.
    White WB, Strand V, Roberts R, Whelton A: Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiin. Amatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004, 11:244–250.PubMedCrossRefGoogle Scholar
  43. 43.
    Farkouh ME, Kirshner H, Harrington R, et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes, randomised controlled trial. Lancet 2004, 364:675–684.PubMedCrossRefGoogle Scholar
  44. 44.
    McAdam BF, Catella-Lawson F, Mardini IA, et al.: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999, 96:272–277.PubMedCrossRefGoogle Scholar
  45. 45.
    FitzGerald GA: Coxibs and cardiovascular disease. N Engl J Med 2004, 351:1709–1711.PubMedCrossRefGoogle Scholar
  46. 46.
    Kobayashi T, Tahara Y, Matsumoto M, et al.: Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004, 114:784–794.PubMedCrossRefGoogle Scholar
  47. 47.
    Catella-Lawson F, McAdam B, Morrison BW, et al.: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999, 289:735–741.PubMedGoogle Scholar
  48. 48.
    Buerkle MA, Lehrer S, Sohn HY, et al.: Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 2004, 110:2053–2059.PubMedCrossRefGoogle Scholar
  49. 49.
    Pidgeon GP, Tamosiuniene R, Chen G, et al.: Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 2004, 110:2701–2707.PubMedCrossRefGoogle Scholar
  50. 50.
    Inoue H, Taba Y, Miwa Y, et al.: Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2002, 22:1415–1420.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Centro Regionale per la Prevenzione dell’AterosclerosiChietiItaly

Personalised recommendations